Drug Profile
Research programme: adoptive T-cell therapies - Eutilex
Alternative Names: CTAG1B-induced natural T cell therapy - Eutilex; HPV 4-1BB CTL - Eutilex; HPV-induced adoptive T cell therapy - Eutilex; HPViNT - Eutilex; Human pappilomavirus-induced natural T cell therapy - Eutilex; Mesothelin 4-1BB CTL - Eutilex; Mesothelin-induced adoptive T cell therapy - Eutilex; Mesothelin-induced natural T cell therapy - Eutilex; MesotheliniNT - Eutilex; NYESOiNT - Eutilex; NYESOiNT 4-1BB CTL - EutilexLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Eutilex
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action CD8 positive T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral, Infusion)
- 06 Nov 2017 Preclinical trials in Cancer in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)
- 06 Nov 2017 Eutilex files an IND application for Mesothelin-induced adoptive T cell therapy in Cancer before November 2017 (Eutilex website, November 2017)